Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGRANEX in diabetic foot ulcers
NCT00034788Phase 3Terminated
- Sponsor
- Johnson & Johnson
- Start
- Dec 2000
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
A Phase 3 trial of becaplermin in diabetic foot ulcer (DFU), sponsored by Johnson & Johnson. Started Dec 2000; status: terminated.
02
Drugs
becaplermin
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT00034788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034788.